Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary Shares by various directors and executives on January 9, 2014. These acquisitions resulted from the reinvestment of dividends paid on shares held in the GlaxoSmithKline ShareReward Plan. The purchase price was 1622.61 pence per Ordinary Share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of specific share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Date: January 9, 2014.
- Share Price: 1622.61 pence per Ordinary Share.
- Transaction Type: Dividend reinvestment via the ShareReward Plan.
- Key Participants: Sir Andrew Witty (28 shares), Mr S M Bicknell (42 shares), Mr D S Redfern (42 shares), Ms C Thomas (42 shares), and others.
- Notification Date: January 10, 2014.